While legumain is associated with increased metastatic potential and worse patient outcomes in both colorectal and gastric cancers (Haugen et al., 2015; Wang, Zhang, et al., 2020), the direct association of legumain‐mediated effects in this context warrants further investigation. The gene discussed is LGMN; the disease is gastric cancer.